Travere Therapeutics and CSL Vifor Announce Standard EU Approval of FILSPARI® (sparsentan) for IgA NephropathyBusiness Wire • 04/29/25
CSL Vifor and Travere Therapeutics announce standard EU approval for FILSPARI® in IgA NephropathyPRNewsWire • 04/29/25
Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the National Kidney Foundation Spring Clinical Meetings 2025Business Wire • 03/31/25
Two S&P 500 Giants And Biotech Play Lead Five Stocks To Watch As Market StrugglesInvestors Business Daily • 03/29/25
Travere Therapeutics Submits sNDA to FDA for Approval of FILSPARI® (sparsentan) for the Treatment of FSGSGlobeNewsWire • 03/17/25
Compared to Estimates, Travere (TVTX) Q4 Earnings: A Look at Key MetricsZacks Investment Research • 02/21/25
Travere Therapeutics (TVTX) Reports Q4 Loss, Tops Revenue EstimatesZacks Investment Research • 02/20/25
Travere Therapeutics Reports Fourth Quarter and Full Year 2024 Financial ResultsGlobeNewsWire • 02/20/25
Curious about Travere (TVTX) Q4 Performance? Explore Wall Street Estimates for Key MetricsZacks Investment Research • 02/17/25
Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial ResultsGlobeNewsWire • 02/13/25
Travere Therapeutics (TVTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 ReleaseZacks Investment Research • 02/13/25
Travere Therapeutics Skyrockets After Reaching FDA Deal For Kidney Disease DrugInvestors Business Daily • 02/11/25
Wall Street Analysts Believe Travere (TVTX) Could Rally 42.56%: Here's is How to TradeZacks Investment Research • 01/08/25
Travere Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/06/25
Homocystinuria Therapeutics Market Research 2024: Insights About 3+ Companies and 3+ Pipeline Drugs Featuring Travere Therapeutics and Syntis BioGlobeNewsWire • 12/18/24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc. - TVTXAccesswire • 11/27/24
Kidney Disease Leader Travere Therapeutics Pulls Back To Key LevelInvestors Business Daily • 11/19/24